Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ANAPTYSBIO SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AnaptysBio, Inc. - ANAB

ANAB

NEW ORLEANS

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilMay 26, 2020 to file lead plaintiff applications in a securities class action lawsuit against AnaptysBio, Inc. (NasdaqGS: ANAB), if they purchased the Company’s shares between October 10, 2017 and November 7, 2019, both dates inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.

What You May Do

If you purchased shares of AnaptysBio and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-anab/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 26, 2020.

About the Lawsuit

AnaptysBio's and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On November 8, 2019, the Company disclosed “very disappoint[ing]” data from its trial evaluating the efficacy of its lead product, etokimab, in patients with moderate-to-severe atopic dermatitis and that as a result, it had postponed the initiation of its Phase 2b etokimab clinical trial in asthma.

On this news, the price of AnaptysBio’s shares plummeted nearly 72%, from a closing price of $36.16 per share on November 7, 2019 to a closing price of $10.18 on November 8, 2019.

The case is City of Hallandale Beach Police Officers et al v. Anaptysbio, Inc., et al., 20-cv-01796.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today